Free Trial
→ Don't lose access to this (From TradeWins) (Ad)tc pixel
NYSEAMERICAN:STXS

Stereotaxis Q3 2026 Earnings Date & Estimates

Stereotaxis logo
$0.82 -0.06 (-6.60%)
As of 01:37 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Stereotaxis is estimated to report Q3 2026 earnings on Tuesday, November 10, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Stereotaxis in Q3 2026

Stereotaxis is expected to post earnings of -$0.0533 per share on revenue of $9.60 million. Stereotaxis last reported on August 11, 2026, posting -$0.05 per share and matching the -$0.05 consensus estimate. Stereotaxis has beaten the consensus EPS estimate in 1 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.0533
Expected Revenue
$9.60 million

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.05 (Met Expectations)
Last Quarter Revenue
$7.67 million
EPS Beat Rate
1 of last 8 quarters

Prepare for the Q3 2026 Call

Stereotaxis Q3 2026 Earnings FAQ

Stereotaxis (NYSEAMERICAN:STXS) is estimated to report Q3 2026 earnings on Tuesday, November 10, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Stereotaxis' Q3 2026 earnings conference call is scheduled for Tuesday, November 10, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Stereotaxis to post earnings of -$0.0533 per share for Q3 2026.

The consensus revenue estimate for Stereotaxis is $9.60 million for Q3 2026.

Stereotaxis Earnings Headlines

Canon Medical, Stereotaxis Partner On Robotic Electrophysiology Labs
November 2 at 10:35 PM  |  rttnews.comhttps://www.rttnews.com/3707063/canon-medical-stereotaxis-partner-on-robotic-electrophysiology-labs.aspx
First-in-Human Coronary Intervention Study Results of Robocath’s Next-Generation Robotic System Highlighted at TCT
November 2 at 10:35 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/first-human-coronary-intervention-study-134800298.html
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.tc pixel
November 3 at 1:00 AM  |  Porter & Company (Ad)
First-in-Human Coronary Intervention Study Results of Robocath's Next-Generation Robotic System Highlighted at TCT
November 2 at 9:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/11/02/3393182/21634/en/first-in-human-coronary-intervention-study-results-of-robocath-s-next-generation-robotic-system-highlighted-at-tct.html
Canon Medical Systems USA, Inc. and Stereotaxis, Inc. Collaborate to Advance Robotic Electrophysiology
October 31 at 2:36 PM  |  marketscreener.comM
Canon Medical and Stereotaxis Collaborate to Advance Robotic Electrophysiology
October 31 at 2:36 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/canon-medical-stereotaxis-collaborate-advance-120300612.html
See More Stereotaxis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Stereotaxis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Stereotaxis and other key companies, straight to your email.

About Stereotaxis

Stereotaxis (NYSEAMERICAN:STXS), Inc. develops robotic technologies for minimally invasive endovascular procedures, with a primary focus on cardiac electrophysiology. Its systems use magnetic navigation and specialized software to help physicians control guidewires and catheters during procedures such as the treatment of cardiac arrhythmias.

The company’s product portfolio includes the Genesis Robotic Magnetic Navigation System, which is designed to provide precise catheter movement and navigation within the heart. Stereotaxis also offers related procedural tools and imaging, data-management, and workflow technologies intended to support physicians and clinical teams in electrophysiology laboratories.

Founded in 1990 and headquartered in St. Louis, Missouri, Stereotaxis serves hospitals and medical centers in the United States and international markets. Its robotic systems have been adopted by institutions worldwide as part of the company’s effort to expand the use of robotic assistance in interventional cardiology and other endovascular procedures.

View Stereotaxis Profile
Earnings Tools